Arbutus Biopharma Corp (ABUS) Operating cash flow 2016–2025
Arbutus Biopharma Corp (ABUS) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$39.6MFY2025 · since FY2016: -$57.9M → -$39.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$39.6M | +38.9% |
| FY2024 | -$64.8M | +24.5% |
| FY2023 | -$85.9M | -143.1% |
| FY2022 | -$35.4M | +47.6% |
| FY2021 | -$67.5M | -31.3% |
| FY2020 | -$51.4M | +27.6% |
| FY2019 | -$71.0M | -4.6% |
| FY2018 | -$67.9M | -39.5% |
| FY2017 | -$48.6M | +16.0% |
| FY2016 | -$57.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ABUS financial trends
ABUS RevenueABUS Net incomeABUS Net marginABUS Gross profitABUS Gross marginABUS Operating incomeABUS Operating marginABUS Free cash flowABUS Capital expendituresABUS Return on equityABUS Stock buybacksABUS Dividends paidABUS Total assetsABUS Total liabilitiesABUS Shareholders’ equityABUS overview →